Troyer D - Search Results

1

Biomarkers for prostate cancer detection.

Parekh DJ, Ankerst DP, Troyer D, Srivastava S, Thompson IM. Parekh DJ, et al. Among authors: troyer d. J Urol. 2007 Dec;178(6):2252-9. doi: 10.1016/j.juro.2007.08.055. Epub 2007 Oct 22. J Urol. 2007. PMID: 17936845 Review.

2

Epididymal rhabdomyoma.

Matsunaga GS, Shepherd DL, Troyer DA, Thompson IM. Matsunaga GS, et al. Among authors: troyer da. J Urol. 2000 Jun;163(6):1876. J Urol. 2000. PMID: 10799212 No abstract available.

3

A reliable assessment of 8-oxo-2-deoxyguanosine levels in nuclear and mitochondrial DNA using the sodium iodide method to isolate DNA.

Hamilton ML, Guo Z, Fuller CD, Van Remmen H, Ward WF, Austad SN, Troyer DA, Thompson I, Richardson A. Hamilton ML, et al. Among authors: troyer da. Nucleic Acids Res. 2001 May 15;29(10):2117-26. doi: 10.1093/nar/29.10.2117. Nucleic Acids Res. 2001. PMID: 11353081 Free PMC article.

4

Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men.

Balic I, Graham ST, Troyer DA, Higgins BA, Pollock BH, Johnson-Pais TL, Thompson IM, Leach RJ. Balic I, et al. J Urol. 2002 Nov;168(5):2245-8. doi: 10.1016/S0022-5347(05)64364-9. J Urol. 2002. PMID: 12394768

5

Genetic fieldwork for hereditary prostate cancer studies.

Plaetke R, Thompson I, Sarosdy M, Harris JM, Troyer D, Arar NH. Plaetke R, et al. Among authors: troyer d. Urol Oncol. 2002 Jan-Feb;7(1):19-27. doi: 10.1016/s1078-1439(01)00132-6. Urol Oncol. 2002. PMID: 12474537

6

Risk perceptions among patients and their relatives regarding prostate cancer and its heredity.

Arar N, Thompson I, Sarosdy M, Harris M, Shepherd D, Troyer D, Plaetke R. Arar N, et al. Among authors: troyer d. Prostate Cancer Prostatic Dis. 2000 Nov;3(3):176-185. doi: 10.1038/sj.pcan.4500416. Prostate Cancer Prostatic Dis. 2000. PMID: 12497094

7

Challenges and opportunities to the design and implementation of chemoprevention trials for prostate cancer.

Thompson IM, Basler JA, Leach R, Troyer D, Klein E, Brawley O. Thompson IM, et al. Among authors: troyer d. Urol Oncol. 2003 Jan-Feb;21(1):73-8. doi: 10.1016/s1078-1439(02)00302-2. Urol Oncol. 2003. PMID: 12684131 Review.

8

Chemoprevention of prostate cancer. Focus on key opportunities and clinical trials.

Leach R, Pollock B, Basler J, Troyer D, Naylor S, Thompson IM. Leach R, et al. Among authors: troyer d. Urol Clin North Am. 2003 May;30(2):227-37. doi: 10.1016/s0094-0143(02)00178-7. Urol Clin North Am. 2003. PMID: 12735500 Review.

9

5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.

Thomas LN, Douglas RC, Vessey JP, Gupta R, Fontaine D, Norman RW, Thompson IM, Troyer DA, Rittmaster RS, Lazier CB. Thomas LN, et al. Among authors: troyer da. J Urol. 2003 Nov;170(5):2019-25. doi: 10.1097/01.ju.0000091804.20183.81. J Urol. 2003. PMID: 14532845

10

Prostate cancer prevention: what do we know now and when will we know more?

Thompson IM, Basler J, Hensley D, von Merveldt D, Jenkins CA, Higgins B, Leach R, Troyer D, Pollock B. Thompson IM, et al. Among authors: troyer d. Clin Prostate Cancer. 2003 Mar;1(4):215-20. doi: 10.3816/cgc.2003.n.002. Clin Prostate Cancer. 2003. PMID: 15040879 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

307 results

Search Page

Filters